Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, today announced its half year results for the six months ended 30 November 2019. Corporate & Operational Highlights Product Commercial Progress..

Oncimmune Holdings plc (LON: ONC), a leading global immunodiagnostics group, is pleased to note that a recent study led by Leeds University Academic Unit of Health Economics, supported by NIHR..

Oncimmune Holdings plc (LON: ONC), a leading global immunodiagnostics group, has announced it has drawn down the second tranche of its previously announced credit facility of €8.5 million with IPF..

Oncimmune Holdings plc (LON: ONC), a leading global immunodiagnostics Group, have announced the completion of the strategic commercialisation agreement with Biodesix, Inc. for EarlyCDT Lung in the United States, which..

Oncimmune Holdings plc (LON: ONC), the leading global immunodiagnostics group, today announced its preliminary unaudited full year results for the year ended 31 May 2019. The audited full year results..

Oncimmune Holdings plc (LON: ONC), a leading global immunodiagnostics group, has today announced the appointment of Professor Tariq Sethi as Chief Scientific Officer, Matthew Luttrell as Chief Commercial Officer and..

Oncimmune Holdings plc (LON: ONC), a Leading Global Immunodiagnostics Group, will be keynoting the China BioMed Innovation and Investment Conference (CBIIC) on Sunday 22nd September 2019, at 9:00 am CST..

Oncimmune Holdings plc (LON:ONC), a leading global immunodiagnostics group, today welcomed the presentation of data today by Professor Frank Sullivan (Chief Investigator on the ECLS trial) which has demonstrated the..

Oncimmune Holdings PLC (LON:ONC), a Leading Global Immunodiagnostics Group, will be presenting at the Solebury Trout European Biotech Investor Day today, Thursday 1st August 2019, at 11.30 am EDT (16:30 BST) in New..

Oncimmune Holdings plc (LON: ONC), a leading global immunodiagnostics group, has today announced Sabartech S.L., its existing distributor in Spain and Portugal, has successfully signed an agreement with Vithas Group,..

Commercialisation partnership with R-Pharm for use of EarlyCDT® Lung in screening for early detection of lung cancer Oncimmune to receive revenues of at least £5 million, including milestone payments of..

Oncimmune Holdings plc (LON: ONC), a leading global immunodiagnostics group, today announced that it has entered into an exclusive partnership agreement which the Board believes will unlock the full potential..

Oncimmune Holdings plc (LON: ONC), a leading global immunodiagnostics group, today provided the following business update for the year ended 31 May 2019. ECLS On 4 June 2019, the Company..

Oncimmune Holdings plc (LON: ONC), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, has today announced that its distributor..

Oncimmune Holdings plc (LON: ONC), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, and its partner, Genostics Company Limited,..

Oncimmune Holdings plc (LON: ONC), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, has today announced that it has..

Oncimmune Holdings plc (LON: ONC), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, today announced the appointment of Dr...

Oncimmune Holdings plc (LON: ONC), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, has today announced its distributor in..